


Formal Synthesis of (–)-Codeine by Application of Temporary Thio Derivatization

Julia Rautschek, Anne Jäger, and Peter Metz*¹

Fakultät Chemie und Lebensmittelchemie, Organische Chemie I, Technische Universität Dresden, Bergstrasse 66, 01069 Dresden, Germany


S Supporting Information

ABSTRACT: Desymmetrization of a *p*-quinone monoacetal by organocatalytic sulfa-Michael addition provided rapid access to a C-ring building block for a formal synthesis of (–)-codeine. By means of a diastereoselective 1,2-addition for A/C-ring union, an intramolecular nitronc cycloaddition for construction of the phenanthrene core, and a sulfoxide elimination, an enantiopure key intermediate of the authors' previous synthesis of racemic codeine was available in 12 steps from isovanillin.



Despite groundbreaking changes in medicine during the past centuries, (–)-morphine (**1**) and (–)-codeine (**2**) have remained indispensable drugs for the treatment of pain (Scheme 1).¹ Produced from the opium poppy (*Papaver somniferum*) until the present time, these alkaloids have been a challenging synthetic target ever since the structure proposal for morphine by Robinson in 1925.² More than 30 total and formal syntheses^{3,4} give evidence of the enormous interest of the scientific

Scheme 1. Retrosynthetic Analysis



community. These endeavors contribute to the development of flexible routes toward morphine and ensure a certain independence from poppy cultivation.^{3b}

In 2011 we disclosed a total synthesis of (±)-codeine (**2**) featuring an intramolecular nitronc cycloaddition to construct the ABC-ring system with simultaneous generation of four contiguous stereogenic centers.⁵ We recently turned to the enantioselective preparation of the key isoxazolidine **3**. We planned to carry out the crucial cycloaddition step from a chiral precursor in which an olefin was temporarily masked with a phenylthio group instead of the prochiral *p*-quinone ether used before. This concept of desymmetrization by reversible thiol addition has been applied previously in enantioselective synthesis by the Figueredo, Evans, and Roberts groups.^{6–8}

As depicted in Scheme 1, we reasoned that enantiopure **3** could be synthesized from β -sulfenyl ketone **4** (path A) or α -sulfenyl ketone **5** (path B). Depending on the position of the phenylthio group, reinstallation of the double bond might be achieved by base-promoted elimination (path A) or thermal elimination of the corresponding sulfoxide (path B). Construction of aldehyde **4** could involve 1,2-addition to known chiral enone **6**.^{9,10} For path B, an analogous disconnection leads to dimethyl acetal **7** as the C-ring unit, the racemic mixture of which is known.¹¹ Both enones could be synthesized by enzymatic kinetic resolution of allylic alcohol (±)-**8**, an approach based on the previous preparation of **6**, where the analogous ethylene acetal was used.¹² Alternatively, asymmetric sulfa-Michael addition¹³ of thiophenol to the corresponding *p*-quinone monoacetal might enable more rapid access to the desired enones.


The absolute configuration at the benzylic carbon in **4** and **5** depends on both the choice of the starting enantiomers and the stereochemical outcome of the A/C-ring union. In order to

Received: December 21, 2017

correctly install the *S* stereogenic center required for the synthesis of (–)-codeine (**2**), preliminary examinations were undertaken. They revealed that nucleophilic 1,2-addition of the respective A-ring fragments to ketones **6** and **7** took place exclusively *anti* to the sulfenyl group, leading to (4*S*,6*R*)-**6** and (*S*)-**7** as the required C-ring units.

For the enzymatic route, allylic alcohol (±)-**8** was readily prepared by base-mediated addition of thiophenol¹¹ to dienone **9** and subsequent diastereoselective 1,2-reduction (Scheme 2).¹⁴

Scheme 2. Enantioselective Synthesis of Enones **6** and (+)-**7**




Pleasingly, enantioselective acetylation catalyzed by *Candida antarctica* lipase B yielded alcohol (+)-**8** and acetate (–)-**10** with excellent enantiomeric excesses.^{15,16} Oxidation of (+)-**8** using Dess–Martin periodinane (DMP) led to enone (*S*)-(+)-**7**, while methanolysis of (–)-**10**, silylation of the resulting alcohol, and

subsequent acetal cleavage¹⁷ in (+)-**11** gave enone (4*S*,6*R*)-**6**. The latter sequence offers an alternative to the previous route toward **6** with improved yield and *ee*.

We continued with the direct organocatalytic preparation of (+)-**7** from *p*-quinone monoacetal **9**. Our studies of the sulfa-Michael addition to **9** delivered very satisfying results comparable to those reported for enones by Singh and co-workers.¹⁸ Best *ee* values of 90% were obtained with only a 0.5 mol % loading of quinidine-based catalyst **12**¹⁹ in toluene at room temperature. Interestingly, both higher and lower catalyst loadings and lower reaction temperature led to decreased enantioselectivity. Recrystallization of the product raised the *ee* to >99% and provided crystals suitable for X-ray diffraction analysis, which confirmed the absolute configuration of (+)-**7** as *S*. This efficient route to (+)-**7** can additionally be utilized for a rapid synthesis of **6** using the pseudoenantiomeric quinine-based catalyst.²⁰


Having gained access to the C-ring building blocks, investigation of the A/C-ring union for path A was undertaken (Scheme 3). The required aromatic A-ring fragment **13** was synthesized from isovanillin (**14**) under optimization of our previous route:²¹ Wittig reaction of aldehyde **15**^{22,23} to give **16**²⁴ followed by hydroboration/oxidation and silyl protection furnished **13**. Halogen–lithium exchange with **6** in the presence of the LaCl₃·2LiCl complex²⁵ resulted in the formation of the tertiary alcohol as a single diastereomer, which was methylated to give **17**. The configuration at the benzylic stereogenic center was assigned on the basis of NOE experiments. Desilylation and oxidation then provided cycloaddition precursor **4** in very good yield. It was subjected to nitron generation/cycloaddition using our previously established conditions⁵ with additional dilution (0.01 M). We isolated a highly unstable product matching the expected ¹H NMR and MS data. It was quickly reduced with NaBH₄ in order to confirm the structure. Unfortunately, the resulting alcohol **18** exhibited the undesired H8,H9 *cis* relationship.²⁶ No other isoxazolidine was isolable after variation of the solvent (dichloromethane) and reaction temperature (–40 °C). The cycloaddition product thus results from a different transition state geometry (*exo*) than that operating in the racemic route (*endo*).²⁷ These findings could be attributed to the higher steric constraints due to the additional sulfenyl group. The *exo/endo* selectivity of nitron cycloadditions is in fact not clearly predictable,²⁸ and different outcomes have been described for cycloadditions similar to the one reported herein.^{26,29}

Scheme 3. Synthesis of Cycloaddition Precursor **4** (Path A) and Its Conversion into *cis*-Isoxazolidine **18**



As the nitron derived from aldehyde **4** failed to undergo cycloaddition with the desired diastereoselectivity, we focused on the synthesis of aldehyde **5** (path B). A/C-ring union was conducted analogously to path A with the known aryl bromide **19**⁵ and enone (+)-**7** to give tertiary alcohol **20** in good yield as a single diastereomer (Scheme 4). Its relative configuration was


Scheme 4. Rapid Access to Cycloaddition Precursor 5 (Path B)



confirmed by X-ray diffraction analysis. Methylation of the alcohol afforded ether **21**, which smoothly underwent double acetal cleavage with a catalytic amount of ceric ammonium nitrate³⁰ to afford aldehyde **5** in excellent yield.

Gratifyingly, subsequent nitron cycloaddition using aldehyde **5** proceeded with formation of the desired H8,H9 *trans* product, but sulfonyl ketone **22c** epimerized at C12 was isolated along with phenanthrene **23** after column chromatography (Scheme 5). Initially, however, isoxazolidines **22a** and **22b** were formed, as

Scheme 5. Assembly of the Phenanthrene Core from 5 by Intramolecular Nitron Cycloaddition




was shown by reduction of the crude mixture to give alcohols **24a** and **24b** in 42% and 22% yield, respectively.³¹ Furthermore, **22a** could be isolated by crystallization. It epimerized to **22c** upon standing without formation of **23**. We therefore concluded that **23** originated exclusively from *cis*-isoxazolidine **22b**.

In principle, the required reinstatement of the alkene by sulfoxide elimination might be realized at the stage of the alcohol or ketone. From the relevant H8,H9 *trans* products, alcohol **24a** exhibited the undesired β -OH configuration at C11, so we focused on the synthesis of **22c**. Eventually we found that the cycloaddition/epimerization sequence was best carried out as a one-pot process with spontaneous epimerization at 0 °C, giving **22c** in 52% yield from **5**.

We then examined the reduction of **22c**, which proceeded with complete diastereoselectivity in high yield (Scheme 6). After

Scheme 6. Completion of the Formal Synthesis of (-)-Codeine (2) by Preparation of 3



protection of the alcohol, silyl ether **25** was oxidized with H₂O₂ in hexafluoroisopropanol (HFIP)³² to give a separable mixture of diastereomeric sulfoxides **26a** and **26b**. Unfortunately, neither sulfoxide underwent elimination to afford olefin **3** at temperatures up to 160 °C. Presumably, the required conformation for *syn* elimination could not be adopted because of restricted rotation around the C–S bond. An alternative elimination of a phenyl sulfilimine generated in situ by reaction of **25** with *O*-mesitylenesulfonylhydroxylamine³³ proved unsuccessful, too. Subsequently, we investigated an oxidation/elimination/reduction sequence starting from **22c**. Although the derived sulfoxides turned out to be prone to phenanthrene formation analogous to the generation of **23**, we were able to gain access to allylic alcohol **27** in a good overall yield of 38% over three steps. Silylation of **27** finally led to the target compound **3**.

In conclusion, we have accomplished a formal synthesis of (-)-codeine (**2**) by straightforward construction of the enantiopure key intermediate **3** in 12 steps from isovanillin. Central to our approach was the temporary installation of a phenylthio group for desymmetrization. We examined two pathways differing in the position of the sulfonyl group and found that only the α -sulfonyl ketone could be used to generate the desired diastereomer in the key intramolecular nitron cycloaddition step. The latter thio derivative **5** was readily available through a highly enantioselective sulfa-Michael addition to *p*-quinone monoacetal **9**, a reaction that should prove useful beyond the application reported herein.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/acs.orglett.7b03972](https://doi.org/10.1021/acs.orglett.7b03972).

Experimental procedures, spectroscopic data, ¹H and ¹³C NMR spectra, and HPLC traces (PDF)

Accession Codes

CCDC 1578109 and 1578110 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, U.K.; fax: +44 1223 336033.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: peter.metz@chemie.tu-dresden.de.

ORCID

Peter Metz: 0000-0002-0592-9850

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by the Deutsche Forschungsgemeinschaft (ME 776/22-1) and the Graduate Academy of TU Dresden funded by the Excellence Initiative of the German Federal and State Governments (scholarship to J.R.).

■ REFERENCES

- (1) WHO Model List of Essential Medicines, 20th List (March 2017); World Health Organization: Geneva, 2017; http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017_FINAL_amendedAug2017.pdf?ua=1.
- (2) Robinson, R.; Gulland, J. M. *Mem. Proc. - Manchester Lit. Philos. Soc.* **1925**, *69*, 79.
- (3) For recent reviews, see: (a) Reed, J. W.; Hudlicky, T. *Acc. Chem. Res.* **2015**, *48*, 674. (b) Rinner, U.; Hudlicky, T. *Top. Curr. Chem.* **2012**, *309*, 33. (c) Chida, N. *Top. Curr. Chem.* **2010**, *299*, 1.
- (4) For total and formal syntheses of morphine and codeine since 2015, see: (a) Li, Q.; Zhang, H. *Chem. - Eur. J.* **2015**, *21*, 16379. (b) Rycek, L.; Hayward, J. J.; Latif, M. A.; Tanko, J.; Simionescu, R.; Hudlicky, T. *J. Org. Chem.* **2016**, *81*, 10930. (c) Chu, S.; Münster, N.; Balan, T.; Smith, M. D. *Angew. Chem., Int. Ed.* **2016**, *55*, 14306; *Angew. Chem.* **2016**, *128*, 14518. (d) Umihara, M.; Yokoshima, S.; Inoue, M.; Fukuyama, T. *Chem. - Eur. J.* **2017**, *23*, 6993. (e) Park, K. H.; Chen, R.; Chen, D. Y.-K. *Chem. Sci.* **2017**, *8*, 7031.
- (5) Erhard, T.; Ehrlich, G.; Metz, P. *Angew. Chem., Int. Ed.* **2011**, *50*, 3892; *Angew. Chem.* **2011**, *123*, 3979.
- (6) (a) de March, P.; Escoda, M.; Figueredo, M.; Font, J.; Alvarez-Larena, A.; Piniella, J. F. *J. Org. Chem.* **1997**, *62*, 7781. (b) Fresneda, M. Á.; Alibés, R.; Bayón, P.; Figueredo, M. *Eur. J. Org. Chem.* **2016**, 3568.
- (7) (a) O'Byrne, A.; Murray, C.; Keegan, D.; Palacio, C.; Evans, P.; Morgan, B. S. *Org. Biomol. Chem.* **2010**, *8*, 539. (b) O'Byrne, A.; O'Reilly, S.; Tighe, C.; Evans, P.; Ciuffini, L.; Santoro, M. G. *Tetrahedron Lett.* **2012**, *53*, 5936.
- (8) Morgan, B. S.; Hoenner, D.; Evans, P.; Roberts, S. M. *Tetrahedron: Asymmetry* **2004**, *15*, 2807.
- (9) Alibés, R.; de March, P.; Figueredo, M.; Font, J.; Marjanet, G. *Tetrahedron: Asymmetry* **2004**, *15*, 1151.
- (10) Bayón, P.; Marjanet, G.; Toribio, G.; Alibés, R.; de March, P.; Figueredo, M.; Font, J. *J. Org. Chem.* **2008**, *73*, 3486.
- (11) de March, P.; Escoda, M.; Figueredo, M.; Font, J.; Medrano, J. *An. Quim. Int. Ed.* **1997**, *93*, 81.

(12) In this work, application of the ethylene acetal was not feasible, as preliminary investigations of path B showed that ethylene acetal cleavage to give **5** was unsuccessful because of competing side reactions.

(13) For recent reviews, see: (a) Chauhan, P.; Mahajan, S.; Enders, D. *Chem. Rev.* **2014**, *114*, 8807. (b) Heravi, M. M.; Hajiabbasi, P. *Mol. Diversity* **2014**, *18*, 411. (c) Enders, D.; Lüttgen, K.; Narine, A. A. *Synthesis* **2007**, 959.

(14) de March, P.; Escoda, M.; Figueredo, M.; Font, J.; García-García, E.; Rodríguez, S. *Tetrahedron: Asymmetry* **2000**, *11*, 4473.

(15) Absolute configurations were assigned after oxidation of (+)-**8** and comparison of specific rotation and chiral HPLC data with those for (+)-**7** from organocatalytic sulfa-Michael addition.

(16) For kinetic resolution of the analogous ethylene acetal,¹⁰ *ee* values of 81% for the alcohol and 95% for the acetate were obtained.

(17) Sun, J.; Dong, Y.; Cao, L.; Wang, X.; Wang, S.; Hu, Y. *J. Org. Chem.* **2004**, *69*, 8932.

(18) Rana, N. K.; Selvakumar, S.; Singh, V. K. *J. Org. Chem.* **2010**, *75*, 2089.

(19) Greenaway, K.; Dambruoso, P.; Ferrali, A.; Hazelwood, A. J.; Sladojevich, F.; Dixon, D. J. *Synthesis* **2011**, 1880.

(20) Vakulya, B.; Varga, S.; Csámpai, A.; Soós, T. *Org. Lett.* **2005**, *7*, 1967.

(21) Rautschek, J.; Metz, P. *Heterocycles* **2017**, *95*, 1106.

(22) Hazlet, S. E.; Brotherton, R. J. *J. Org. Chem.* **1962**, *27*, 3253.

(23) Sinhababu, A. K.; Borchardt, R. T. *J. Org. Chem.* **1983**, *48*, 2356.

(24) Olefin **16** has been previously reported but not yet characterized. See: Reddy, R.; Naga, C.; Arumugam, S. WO 2013072830 A1, 2013.

(25) Krasovskiy, A.; Kopp, F.; Knochel, P. *Angew. Chem., Int. Ed.* **2006**, *45*, 497; *Angew. Chem.* **2006**, *118*, 511.

(26) For related intramolecular nitrene and nitrile oxide cyclo-additions, see ref **5** and: (a) Endoma-Arias, M. A. A.; Hudlicky, J. R.; Simionescu, R.; Hudlicky, T. *Adv. Synth. Catal.* **2014**, *356*, 333. (b) Parsons, P. J.; Penkett, C. S.; Shell, A. J. *Chem. Rev.* **1996**, *96*, 195. (c) Chandler, M.; Parsons, P. J. *J. Chem. Soc., Chem. Commun.* **1984**, 322.

(27) It is assumed that the more stable (*Z*)-nitrene is present and no conversion takes place at room temperature. See: Aurich, H. G.; Franke, M.; Kesselheim, H. P. *Tetrahedron* **1992**, *48*, 663.

(28) Rastelli, A.; Gandolfi, R.; Amadè, M. S. *Adv. Quantum Chem.* **2000**, *36*, 151.

(29) For example, see: (a) Aurich, H. G.; Geiger, M.; Gentes, C.; Köster, H. *Tetrahedron Lett.* **1996**, *37*, 841. (b) Ishikawa, T.; Kudo, T.; Shigemori, K.; Saito, S. *J. Am. Chem. Soc.* **2000**, *122*, 7633. (c) Shing, T. K. M.; Wong, W. F.; Ikeno, T.; Yamada, T. *Org. Lett.* **2007**, *9*, 207. (d) Majer, R.; Konechnaya, O.; Dello, I.; Tejero, T.; Attanasi, O. A.; Santeusano, S.; Merino, P. *Org. Biomol. Chem.* **2014**, *12*, 8888. (e) Xiang, J.; Zhu, T.; Dang, Q.; Bai, X. *Chem. Heterocycl. Compd.* **2016**, *52*, 601.

(30) Ates, A.; Gautier, A.; Leroy, B.; Plancher, J.-M.; Quesnel, Y.; Vanherck, J.-C.; Markó, I. E. *Tetrahedron* **2003**, *59*, 8989.

(31) While the relative configuration of **24b** could be assigned by NOE experiments, **24a** was subjected to a silylation/oxidation/elimination sequence in order to unambiguously determine the β -OH configuration at C11. See the Supporting Information for more details.

(32) Ravikumar, K. S.; Bégue, J.-P.; Bonnet-Delpon, D. *Tetrahedron Lett.* **1998**, *39*, 3141.

(33) Matsuo, J.; Kozai, T.; Ishibashi, H. *Org. Lett.* **2006**, *8*, 6095.